Premium
Successful treatment of severe psoriasis with basiliximab, an interleukin‐2 receptor monoclonal antibody
Author(s) -
Owen C. M.,
Harrison P. V.
Publication year - 2000
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1046/j.1365-2230.2000.00612.x
Subject(s) - basiliximab , psoriasis , monoclonal antibody , medicine , immunology , il 2 receptor , monoclonal , dermatology , antibody , t cell , immune system , chemotherapy , induction therapy
T‐cell mediated inflammation plays an important role in the aetiology of psoriasis. We describe a case of severe recalcitrant psoriasis responding well to combined cyclosporin and basiliximab (Simulect ® Novartis Pharmaceuticals UK Ltd), an interleukin‐2 receptor (IL‐2R; CD25) chimeric monoclonal antibody.